{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:20:30Z","timestamp":1794360030387,"version":"4.9.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40257-022-00704-0","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T19:36:48Z","timestamp":1658259408000},"page":"689-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas"],"prefix":"10.1007","volume":"23","author":[{"given":"Amanda","family":"Krenitsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skylar","family":"Klager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Hatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Sarriera-Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Seminario-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"issue":"20","key":"704_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"16","key":"704_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703\u201314.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"704_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hon.2584","volume":"37","author":"W Kempf","year":"2019","unstructured":"Kempf W, Zimmermann AK, Mitteldorf C. Cutaneous lymphomas: an update 2019. Hematol Oncol. 2019;37(Suppl. 1):43\u20137.","journal-title":"Hematol Oncol"},{"issue":"3","key":"704_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cll.2017.05.009","volume":"37","author":"CB Hope","year":"2017","unstructured":"Hope CB, Pincus LB. Primary cutaneous B-cell lymphomas. Clin Lab Med. 2017;37(3):547\u201374.","journal-title":"Clin Lab Med"},{"key":"704_CR5","volume-title":"Clinical practice guidelines in oncology, primary cutaneous B-cell lymphomas version 2.2021","author":"National Comprehensive Cancer Network (NCCN)","year":"2021","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology, primary cutaneous B-cell lymphomas version 2.2021. Fort Washington: National Comprehensive Cancer Network; 2021."},{"key":"704_CR6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3389\/fonc.2020.00988","volume":"10","author":"G Tadiotto Cicogna","year":"2020","unstructured":"Tadiotto Cicogna G, Ferranti M, Alaibac M. Diagnostic workup of primary cutaneous B cell lymphomas: a clinician\u2019s approach. Front Oncol. 2020;10:988.","journal-title":"Front Oncol"},{"issue":"2","key":"704_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"YH Kim","year":"2007","unstructured":"Kim YH, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479\u201384.","journal-title":"Blood"},{"issue":"5","key":"704_CR8","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","volume":"112","author":"NJ Senff","year":"2008","unstructured":"Senff NJ, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma. Consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600\u20139.","journal-title":"Blood"},{"key":"704_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3389\/fonc.2020.00651","volume":"10","author":"P Vitiello","year":"2020","unstructured":"Vitiello P, et al. Primary cutaneous B-cell lymphomas: an update. Front Oncol. 2020;10:651.","journal-title":"Front Oncol"},{"issue":"6","key":"704_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3390\/cancers12061497","volume":"12","author":"M Dumont","year":"2020","unstructured":"Dumont M, Battistella M, Ram-Wolff C, Bagot M, de Masson A. Diagnosis and treatment of primary cutaneous B-cell lymphomas: state of the art and perspectives. Cancers (Basel). 2020;12(6):1497.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"704_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.semdp.2016.11.007","volume":"34","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH. Cutaneous marginal zone lymphomas. Semin Diagn Pathol. 2017;34(1):76\u201384.","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"704_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/bjd.14932","volume":"176","author":"I Amitay-Laish","year":"2017","unstructured":"Amitay-Laish I, et al. Paediatric primary cutaneous marginal zone B-cell lymphoma: does it differ from its adult counterpart? Br J Dermatol. 2017;176(4):1010\u201320.","journal-title":"Br J Dermatol"},{"issue":"4","key":"704_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jamadermatol.2013.9223","volume":"150","author":"J Guitart","year":"2014","unstructured":"Guitart J, et al. High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomas. JAMA Dermatol. 2014;150(4):412\u20138.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"704_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/00000478-200308000-00003","volume":"27","author":"C Li","year":"2003","unstructured":"Li C, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol. 2003;27(8):1061\u20139.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"704_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/00000478-199608000-00010","volume":"20","author":"EM Bailey","year":"1996","unstructured":"Bailey EM, et al. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol. 1996;20(8):1011\u201323.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"704_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/DAD.0b013e318267495f","volume":"35","author":"CM Magro","year":"2013","unstructured":"Magro CM, Yang A, Fraga G. Blastic marginal zone lymphoma: a clinical and pathological study of 8 cases and review of the literature. Am J Dermatopathol. 2013;35(3):319\u201326.","journal-title":"Am J Dermatopathol"},{"issue":"11","key":"704_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/00000478-199711000-00005","volume":"21","author":"L Cerroni","year":"1997","unstructured":"Cerroni L, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol. 1997;21(11):1307\u201315.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"704_CR18","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","volume":"105","author":"JJ Hoefnagel","year":"2005","unstructured":"Hoefnagel JJ, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671\u20138.","journal-title":"Blood"},{"issue":"8","key":"704_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","volume":"24","author":"L Cerroni","year":"1997","unstructured":"Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457\u201361.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"704_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","volume":"28","author":"GS Wood","year":"2001","unstructured":"Wood GS, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28(10):502\u20137.","journal-title":"J Cutan Pathol"},{"issue":"5","key":"704_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.01485.x","volume":"20","author":"I Mandekou-Lefaki","year":"2006","unstructured":"Mandekou-Lefaki I, Delli FS, Kountouras J, Athanasiou E, Mattheou-Vakali G. Primary cutaneous MALT-type lymphoma and Helicobacter pylori: a possible relationship. J Eur Acad Dermatol Venereol. 2006;20(5):606\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"704_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2005.04.036","volume":"53","author":"SA May","year":"2005","unstructured":"May SA, Netto G, Domiati-Saad R, Kasper C. Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination. J Am Acad Dermatol. 2005;53(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"704_CR23","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/modpathol.2008.159","volume":"21","author":"H Takino","year":"2008","unstructured":"Takino H, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. Mod Pathol. 2008;21(12):1517\u201326.","journal-title":"Mod Pathol"},{"issue":"2","key":"704_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.leukres.2013.10.020","volume":"38","author":"S Guastafierro","year":"2014","unstructured":"Guastafierro S, et al. Clinical significance of serum triple monoclonal components: a report of 6 cases and a review of the literature. Leuk Res. 2014;38(2):166\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"704_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.leukres.2012.05.008","volume":"36","author":"S Guastafierro","year":"2012","unstructured":"Guastafierro S, et al. Serum double monoclonal components and hematological malignancies: only a casual association? Review of 34 cases. Leuk Res. 2012;36(10):1274\u20137.","journal-title":"Leuk Res"},{"issue":"1","key":"704_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12788\/j.sder.2018.014","volume":"37","author":"ST Chen","year":"2018","unstructured":"Chen ST, Barnes J, Duncan L. Primary cutaneous B-cell lymphomas: clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):49\u201355.","journal-title":"Semin Cutan Med Surg"},{"issue":"12","key":"704_CR27","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","volume":"34","author":"JT Edinger","year":"2010","unstructured":"Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34(12):1830\u201341.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"704_CR28","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1182\/blood-2008-01-132415","volume":"112","author":"F van Maldegem","year":"2008","unstructured":"van Maldegem F, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood. 2008;112(8):3355\u201361.","journal-title":"Blood"},{"issue":"10","key":"704_CR29","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/PAS.0000000000001363","volume":"43","author":"ED Carlsen","year":"2019","unstructured":"Carlsen ED, Swerdlow SH, Cook JR, Gibson SE. Class-switched primary cutaneous marginal zone lymphomas are frequently IgG4-positive and have features distinct from IgM-positive cases. Am J Surg Pathol. 2019;43(10):1403\u201312.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"704_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ajd.12699","volume":"59","author":"JR Sun","year":"2018","unstructured":"Sun JR, Nong L, Liu XQ, Tu P, Wang Y. Frequent immunoglobulin G4 expression in a common variant of primary cutaneous marginal zone B-cell lymphoma. Australas J Dermatol. 2018;59(2):141\u20135.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"704_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/DAD.0000000000000249","volume":"37","author":"S Machan","year":"2015","unstructured":"Machan S, et al. Primary cutaneous marginal IgG4 lymphoma and Rosai-Dorfman\u2019s disease coexisting in several lesions of the same patient. Am J Dermatopathol. 2015;37(5):413\u20138.","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"704_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/cup.14111","volume":"49","author":"ED Carlsen","year":"2022","unstructured":"Carlsen ED, Bhavsar S, Cook JR, Swerdlow SH. IRTA1 positivity helps identify a MALT-lymphoma-like subset of primary cutaneous marginal zone lymphomas, largely but not exclusively defined by IgM expression. J Cutan Pathol. 2022;49(1):55\u201360.","journal-title":"J Cutan Pathol"},{"issue":"6","key":"704_CR33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1046\/j.1365-2133.2002.04961.x","volume":"147","author":"O Servitje","year":"2002","unstructured":"Servitje O, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147(6):1147\u201358.","journal-title":"Br J Dermatol"},{"issue":"7","key":"704_CR34","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.jid.2018.02.015","volume":"138","author":"K Maurus","year":"2018","unstructured":"Maurus K, et al. Panel sequencing shows recurrent genetic FAS alterations in primary cutaneous marginal zone lymphoma. J Invest Dermatol. 2018;138(7):1573\u201381.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"704_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/10428190500305380","volume":"7","author":"A Lukowsky","year":"2006","unstructured":"Lukowsky A, Marchwat M, Sterry W, Gellrich S. Evaluation of B-cell clonality in archival skin biopsy samples of cutaneous B-cell lymphoma by immunoglobulin heavy chain gene polymerase chain reaction. Leuk Lymphoma. 2006;7(3):487\u201393.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"704_CR36","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/sj.leu.2403501","volume":"18","author":"B Streubel","year":"2004","unstructured":"Streubel B, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18(10):1722\u20136.","journal-title":"Leukemia"},{"key":"704_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/ajh.25970","volume":"95","author":"AC Hristov","year":"2020","unstructured":"Hristov AC, Tejasvi T, Wilcox RA. Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2020;95:1209\u201313.","journal-title":"Am J Hematol"},{"issue":"1","key":"704_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1684\/ejd.2020.3955","volume":"31","author":"A Legrand","year":"2021","unstructured":"Legrand A, et al. Lack of clinical relevance of blood clonality in primary cutaneous marginal zone B-cell lymphoma. Eur J Dermatol. 2021;31(1):94\u20136.","journal-title":"Eur J Dermatol"},{"issue":"2","key":"704_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00066-019-01541-7","volume":"196","author":"M Oertel","year":"2020","unstructured":"Oertel M, Elsayad K, Weishaupt C, Steinbrink K, Eich HT. De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma. Strahlenther Onkol. 2020;196(2):126\u201331.","journal-title":"Strahlenther Onkol"},{"issue":"Suppl. 4","key":"704_CR40","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv30-40.","journal-title":"Ann Oncol"},{"issue":"6","key":"704_CR41","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000241302","volume":"22","author":"A Farkas","year":"2009","unstructured":"Farkas A, Kemeny L, French LE, Dummer R. New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacol Physiol. 2009;22(6):322\u201334.","journal-title":"Skin Pharmacol Physiol."},{"issue":"5","key":"704_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/10428190500399698","volume":"47","author":"A Cozzio","year":"2006","unstructured":"Cozzio A, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma. 2006;47(5):865\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"704_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","volume":"163","author":"A Perry","year":"2010","unstructured":"Perry A, Vincent BJ, Parker SR. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. Br J Dermatol. 2010;163(1):223\u20135.","journal-title":"Br J Dermatol"},{"issue":"1","key":"704_CR44","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","volume":"167","author":"Y Pe\u00f1ate","year":"2012","unstructured":"Pe\u00f1ate Y, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol. 2012;167(1):174\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"704_CR45","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","volume":"155","author":"K Kerl","year":"2006","unstructured":"Kerl K, Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol. 2006;155(6):1197\u2013200.","journal-title":"Br J Dermatol"},{"issue":"10","key":"704_CR46","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373.","journal-title":"Adv Ther"},{"issue":"10","key":"704_CR47","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/0284186X.2021.1956689","volume":"60","author":"M Olszewska-Szopa","year":"2021","unstructured":"Olszewska-Szopa M, et al. Primary cutaneous indolent B-cell lymphomas: a retrospective multicenter analysis and a review of literature. Acta Oncol. 2021;60(10):1361\u20138.","journal-title":"Acta Oncol"},{"issue":"10","key":"704_CR48","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.jid.2019.04.005","volume":"139","author":"MT Koning","year":"2019","unstructured":"Koning MT, et al. Acquired N-linked glycosylation motifs in B-cell receptors of primary cutaneous B-cell lymphoma and the normal B-cell repertoire. J Invest Dermatol. 2019;139(10):2195\u2013203.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"704_CR49","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","volume":"25","author":"NJ Senff","year":"2007","unstructured":"Senff NJ, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25(12):1581\u20137.","journal-title":"J Clin Oncol"},{"issue":"12","key":"704_CR50","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1016\/j.clml.2021.07.021","volume":"21","author":"D Bomze","year":"2021","unstructured":"Bomze D, Sprecher E, Goldberg I, Samuelov L, Geller S. Primary cutaneous B-cell lymphomas in children and adolescents: a SEER population-based study. Clin Lymphoma Myeloma Leuk. 2021;21(12):e1000\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"704_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.semdp.2016.11.006","volume":"34","author":"CB Hope","year":"2017","unstructured":"Hope CB, Pincus LB. Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. Semin Diagn Pathol. 2017;34(1):85\u201398.","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"704_CR52","doi-asserted-by":"publisher","first-page":"329.e1","DOI":"10.1016\/j.jaad.2013.06.012","volume":"69","author":"AL Su\u00e1rez","year":"2013","unstructured":"Su\u00e1rez AL, et al. Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification. J Am Acad Dermatol. 2013;69(3):329.e1-13 (quiz 341\u20132).","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"704_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21037\/tlcr.2019.12.28","volume":"9","author":"A Fiorelli","year":"2020","unstructured":"Fiorelli A, et al. Prognostic factors of lung cancer in lymphoma survivors (the LuCiLyS study). Transl Lung Cancer Res. 2020;9(1):90\u2013102.","journal-title":"Transl Lung Cancer Res."},{"issue":"3","key":"704_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1309\/AJCP4SUBR4NPSPTN","volume":"143","author":"A Pham-Ledard","year":"2015","unstructured":"Pham-Ledard A, et al. Diagnostic and prognostic value of BCL2 rearrangement in 53 patients with follicular lymphoma presenting as primary skin lesions. Am J Clin Pathol. 2015;143(3):362\u201373.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"704_CR55","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jaad.2019.01.037","volume":"81","author":"MK Kheterpal","year":"2019","unstructured":"Kheterpal MK, et al. Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. J Am Acad Dermatol. 2019;81(4):970\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"704_CR56","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.jaad.2015.02.1134","volume":"72","author":"C Massone","year":"2015","unstructured":"Massone C, Fink-Puches R, Wolf I, Zalaudek I, Cerroni L. Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type. J Am Acad Dermatol. 2015;72(6):1016\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"704_CR57","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","volume":"132","author":"MH Vermeer","year":"1996","unstructured":"Vermeer MH, et al. Primary cutaneous large B-cell lymphomas of the legs: a distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol. 1996;132(11):1304\u20138.","journal-title":"Arch Dermatol"},{"issue":"4","key":"704_CR58","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.det.2019.05.004","volume":"37","author":"SJ Malachowski","year":"2019","unstructured":"Malachowski SJ, Sun J, Chen PL, Seminario-Vidal L. Diagnosis and management of cutaneous B-cell lymphomas. Dermatol Clin. 2019;37(4):443\u201354.","journal-title":"Dermatol Clin"},{"issue":"5","key":"704_CR59","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jaad.2010.06.059","volume":"65","author":"A Gulia","year":"2011","unstructured":"Gulia A, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment. J Am Acad Dermatol. 2011;65(5):991\u20131000.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"704_CR60","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/jid.2008.357","volume":"129","author":"NJ Senff","year":"2009","unstructured":"Senff NJ, et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2009;129(5):1149\u201355.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"704_CR61","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","volume":"137","author":"S Mareschal","year":"2017","unstructured":"Mareschal S, et al. Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing. J Invest Dermatol. 2017;137(9):1984\u201394.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"704_CR62","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/modpathol.2013.156","volume":"27","author":"A Pham-Ledard","year":"2014","unstructured":"Pham-Ledard A, et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol. 2014;27(3):402\u201311.","journal-title":"Mod Pathol"},{"issue":"11","key":"704_CR63","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.jid.2019.05.008","volume":"139","author":"O Ducharme","year":"2019","unstructured":"Ducharme O, et al. Mutations of the B-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large B-cell lymphoma leg type. J Invest Dermatol. 2019;139(11):2334-42.e8.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"704_CR64","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","volume":"150","author":"A Pham-Ledard","year":"2014","unstructured":"Pham-Ledard A, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150(11):1173\u20139.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"704_CR65","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","volume":"136","author":"S Menguy","year":"2016","unstructured":"Menguy S, et al. MYD88 somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma. J Invest Dermatol. 2016;136(8):1741\u20134.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"704_CR66","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","volume":"41","author":"C Mitteldorf","year":"2017","unstructured":"Mitteldorf C, et al. Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma: new therapeutic targets. Am J Surg Pathol. 2017;41(7):998\u20131004.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"704_CR67","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/PAS.0000000000000983","volume":"42","author":"S Menguy","year":"2018","unstructured":"Menguy S, et al. PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol. 2018;42(3):326\u201334.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"704_CR68","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","volume":"138","author":"XA Zhou","year":"2018","unstructured":"Zhou XA, et al. Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2018;138(11):2365\u201376.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"704_CR69","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2133.2012.10987.x","volume":"167","author":"M Felcht","year":"2012","unstructured":"Felcht M, et al. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells. Br J Dermatol. 2012;167(2):348\u201358.","journal-title":"Br J Dermatol"},{"issue":"11","key":"704_CR70","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1111\/jdv.14358","volume":"31","author":"E Gardette","year":"2017","unstructured":"Gardette E, et al. Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. J Eur Acad Dermatol Venereol. 2017;31(11):e498-501.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"704_CR71","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/archdermatol.2009.23","volume":"145","author":"F Grange","year":"2009","unstructured":"Grange F, et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol. 2009;145(3):329\u201330.","journal-title":"Arch Dermatol"},{"issue":"3","key":"704_CR72","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1600-0609.2008.01197.x","volume":"82","author":"S Pulini","year":"2009","unstructured":"Pulini S, et al. Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies. Eur J Haematol. 2009;82(3):184\u201393.","journal-title":"Eur J Haematol"},{"issue":"2","key":"704_CR73","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ejh.12315","volume":"93","author":"A Fabbri","year":"2014","unstructured":"Fabbri A, et al. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Eur J Haematol. 2014;93(2):129\u201336.","journal-title":"Eur J Haematol"},{"issue":"4","key":"704_CR74","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ijrobp.2013.07.019","volume":"87","author":"SN Hamilton","year":"2013","unstructured":"Hamilton SN, et al. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. Int J Radiat Oncol Biol Phys. 2013;87(4):719\u201325.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"704_CR75","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist. 2021;26(2):120\u201332.","journal-title":"Oncologist"},{"issue":"21","key":"704_CR76","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMct1114348","volume":"366","author":"DG Maloney","year":"2012","unstructured":"Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008\u201316.","journal-title":"N Engl J Med"},{"key":"704_CR77","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fonc.2019.01238","volume":"9","author":"G Tadiotto Cicogna","year":"2019","unstructured":"Tadiotto Cicogna G, Ferranti M, Lazzarotto A, Alaibac M. Biological approaches to aggressive cutaneous B-cell lymphomas. Front Oncol. 2019;9:1238.","journal-title":"Front Oncol"},{"key":"704_CR78","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1749-6632.2012.06661.x","volume":"1263","author":"IV Gupta","year":"2012","unstructured":"Gupta IV, Jewell RC. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci. 2012;1263:43\u201356.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"704_CR79","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/10428194.2016.1207764","volume":"58","author":"N Galanina","year":"2017","unstructured":"Galanina N, Jasielec J, Peace D, Smith SM, Nabhan C. Ofatumumab monotherapy in relapsed\/refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2017;58(3):752\u20133.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"704_CR80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bjh.15768","volume":"185","author":"CA Rosenbaum","year":"2019","unstructured":"Rosenbaum CA, et al. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol. 2019;185(1):53\u201364.","journal-title":"Br J Haematol"},{"issue":"4","key":"704_CR81","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.4081\/rt.2015.6067","volume":"7","author":"E Gupta","year":"2015","unstructured":"Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW. Excellent outcome of immunomodulation or Bruton\u2019s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Rare Tumors. 2015;7(4):6067.","journal-title":"Rare Tumors."},{"issue":"6","key":"704_CR82","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.clml.2014.11.003","volume":"15","author":"SE Mancebo","year":"2015","unstructured":"Mancebo SE, Smith JR, Intlekofer AM, Zelenetz AD, Myskowski PL. Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy. Clin Lymphoma Myeloma Leuk. 2015;15(6):e113\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"704_CR83","unstructured":"FDA. Product approval onformation: licensing action Zevalin (ibritumomab tiuxetan). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/125019_0000_ZevalinTOC.cfm\/. Accessed 29 Oct 2021."},{"key":"704_CR84","unstructured":"FDA. Product approval information: licensing action tositumomab. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2003\/tosicor062703L.htm. Accessed 29 Oct 2021."},{"issue":"1","key":"704_CR85","first-page":"13","volume":"36","author":"A Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez A, et al. Radioimmunotherapy for non-Hodgkin\u2019s lymphoma; positioning, safety, and efficacy of 90Y-Ibritumomab: 10 years of experience and follow-up. Rev Esp Med Nucl Imagen Mol. 2017;36(1):13\u20139.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"1","key":"704_CR86","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1186\/s12885-020-07715-2","volume":"20","author":"J Wang","year":"2020","unstructured":"Wang J, Huang J, Zeng Q. Network meta-analysis of targeted therapies for diffuse large B cell lymphoma. BMC Cancer. 2020;20(1):1218.","journal-title":"BMC Cancer"},{"issue":"26","key":"704_CR87","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","volume":"27","author":"R Advani","year":"2009","unstructured":"Advani R, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009;27(26):4371\u20137.","journal-title":"J Clin Oncol"},{"key":"704_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-8722-7-44","volume":"7","author":"S de Vos","year":"2014","unstructured":"de Vos S, et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol. 2014;7:44.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"704_CR89","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388.","journal-title":"Lancet Oncol"},{"issue":"8","key":"704_CR90","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","volume":"44","author":"M M\u00f8lh\u00f8j","year":"2007","unstructured":"M\u00f8lh\u00f8j M, et al. CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol. 2007;44(8):1935\u201343.","journal-title":"Mol Immunol"},{"issue":"11","key":"704_CR91","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410\u20136.","journal-title":"Blood"},{"issue":"1","key":"704_CR92","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","volume":"24","author":"J Yu","year":"2019","unstructured":"Yu J, Wang W, Huang H. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin\u2019s lymphoma: a systemic review and meta-analysis. Hematology. 2019;24(1):199\u2013207.","journal-title":"Hematology"},{"issue":"9","key":"704_CR93","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","volume":"61","author":"L Coyle","year":"2020","unstructured":"Coyle L, et al. Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020;61(9):2103\u201312.","journal-title":"Leuk Lymphoma"},{"key":"704_CR94","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/blood-2019-121708","volume":"134","author":"DAC Katz","year":"2019","unstructured":"Katz DAC, David KA, Thieblemont C, Morley NJ, Khan SS, et al. Open-label, phase 2 study of blinatumomab after first-line rituximab-chemotherapy in adults with newly diagnosed, high-risk diffuse large B-cell lymphom. Blood. 2019;134:4077.","journal-title":"Blood"},{"key":"704_CR95","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1182\/blood-2019-124254","volume":"134","author":"CF Poh","year":"2019","unstructured":"Poh CF, Ruel C, Abedi M, Schwab E, Costello CL, Zain J, et al. Blinatumomab\/lenalidomide in relapsed\/refractory non-Hodgkin\u2019s lymphoma: a phase I California Cancer Consortium study of safety, efficacy and immune correlative analysis. Blood. 2019;134:760.","journal-title":"Blood"},{"key":"704_CR96","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJB Schuster","year":"2019","unstructured":"Schuster SJB, Assouline S, Bosch F, Sehn LH, Cheah CY, Ku M, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6.","journal-title":"Blood"},{"key":"704_CR97","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood-2019-122451","volume":"134","author":"R Bannerji","year":"2019","unstructured":"Bannerji R, Arnason JE, Brown JR, Advani RH, Barnes JA, Ansell SM, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 \u00d7 anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134:762.","journal-title":"Blood"},{"key":"704_CR98","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","volume":"132","author":"LE Budde","year":"2018","unstructured":"Budde LE, Assouline S, Flinn IW, Isufi I, Yoon S-S, Kim W-S, et al. Mosunetuzumab, a full-length bispecific CD20\/CD3 antibody, displays clinical activity in relapsed\/refractory B-cell non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132:399.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"704_CR99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-135818","volume":"136","author":"MJ Matasar","year":"2020","unstructured":"Matasar MJ, et al. Subcutaneous mosunetuzumab in relapsed or refractory B-cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts. Blood. 2020;136(Suppl. 1):45\u20136.","journal-title":"Blood"},{"issue":"4","key":"704_CR100","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1172\/JCI129206","volume":"130","author":"SM Ansell","year":"2020","unstructured":"Ansell SM, Lin Y. Immunotherapy of lymphomas. J Clin Invest. 2020;130(4):1576\u201385.","journal-title":"J Clin Invest"},{"issue":"6","key":"704_CR101","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","volume":"37","author":"SM Ansell","year":"2019","unstructured":"Ansell SM, et al. Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients eneligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37(6):481\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"704_CR102","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/bjh.16211","volume":"187","author":"C Di Raimondo","year":"2019","unstructured":"Di Raimondo C, Abdulla FR, Zain J, Querfeld C, Rosen ST. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2019;187(3):e79-82.","journal-title":"Br J Haematol"},{"issue":"23","key":"704_CR103","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-19-0438","volume":"25","author":"JM Tuscano","year":"2019","unstructured":"Tuscano JM, et al. A phase I study of the combination of rituximab and ipilimumab in patients with relapsed\/refractory B-cell lymphoma. Clin Cancer Res. 2019;25(23):7004\u201313.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"704_CR104","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1007\/s00277-019-03787-8","volume":"98","author":"A Pang","year":"2019","unstructured":"Pang A, Au-Yeung R, Leung RYY, Kwong YL. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib. Ann Hematol. 2019;98(10):2433\u20136.","journal-title":"Ann Hematol"},{"issue":"6","key":"704_CR105","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/ijms19061758","volume":"19","author":"LC Fox","year":"2018","unstructured":"Fox LC, et al. Molecular mechanisms of disease progression in primary cutaneous diffuse large B-cell lymphoma, leg type during ibrutinib therapy. Int J Mol Sci. 2018;19(6):1758.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"704_CR106","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jid.2018.03.1516","volume":"138","author":"M Beylot-Barry","year":"2018","unstructured":"Beylot-Barry M, et al. A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol. 2018;138(9):1982\u20139.","journal-title":"J Invest Dermatol"},{"issue":"13","key":"704_CR107","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood.2018891598","volume":"134","author":"A Goy","year":"2019","unstructured":"Goy A, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024\u201336.","journal-title":"Blood"},{"issue":"4","key":"704_CR108","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/bjh.17886","volume":"196","author":"DC Moore","year":"2022","unstructured":"Moore DC, et al. Rituximab, lenalidomide, and ibrutinib in relapsed\/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2022;196(4):e30\u20133.","journal-title":"Br J Haematol"},{"issue":"21","key":"704_CR109","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","volume":"34","author":"M Crump","year":"2016","unstructured":"Crump M, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2016;34(21):2484\u201392.","journal-title":"J Clin Oncol"},{"issue":"16","key":"704_CR110","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","volume":"133","author":"A Forero-Torres","year":"2019","unstructured":"Forero-Torres A, et al. Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133(16):1742\u201352.","journal-title":"Blood"},{"issue":"2","key":"704_CR111","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341\u20137.","journal-title":"Leukemia"},{"issue":"8","key":"704_CR112","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"17","key":"704_CR113","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","volume":"27","author":"MS Davids","year":"2021","unstructured":"Davids MS, et al. Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study. Clin Cancer Res. 2021;27(17):4690\u20135.","journal-title":"Clin Cancer Res"},{"key":"704_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00002","volume":"3","author":"HS Walter","year":"2019","unstructured":"Walter HS, et al. Successful treatment of primary cutaneous diffuse large B-cell lymphoma leg type with single-agent venetoclax. JCO Precis Oncol. 2019;3:1\u20135.","journal-title":"JCO Precis Oncol"},{"key":"704_CR115","unstructured":"FDA. Product approval information: licensing action tisagenlecleucel. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma. Accessed 29 Oct 2021."},{"key":"704_CR116","unstructured":"FDA. Product approval information: licensing action Yescarta (axicabtagene ciloleucel). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel. Accessed 29 Oct 2021."},{"issue":"1","key":"704_CR117","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"26","key":"704_CR118","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"704_CR119","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","volume":"6","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018;6(1):137.","journal-title":"J Immunother Cancer"},{"issue":"7\u20138","key":"704_CR120","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41417-018-0073-7","volume":"26","author":"F Bao","year":"2019","unstructured":"Bao F, et al. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Ther. 2019;26(7\u20138):248\u201355.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"704_CR121","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.beha.2018.07.011","volume":"31","author":"R Nair","year":"2018","unstructured":"Nair R, Neelapu SS. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. 2018;31(3):293\u20138.","journal-title":"Best Pract Res Clin Haematol"},{"key":"704_CR122","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-Hodgkin lymphoma. Front Oncol. 2019;9:767.","journal-title":"Front Oncol"},{"issue":"6","key":"704_CR123","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","volume":"104","author":"R Dummer","year":"2004","unstructured":"Dummer R, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood. 2004;104(6):1631\u20138.","journal-title":"Blood"},{"issue":"2","key":"704_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083670","volume":"9","author":"B Dreno","year":"2014","unstructured":"Dreno B, et al. TG1042 (Adenovirus-interferon-\u03b3) in primary cutaneous B-cell lymphomas: a phase II clinical trial. PLoS ONE. 2014;9(2): e83670.","journal-title":"PLoS ONE"},{"issue":"6","key":"704_CR125","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/mt.2010.52","volume":"18","author":"R Dummer","year":"2010","unstructured":"Dummer R, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010;18(6):1244\u20137.","journal-title":"Mol Ther"},{"key":"704_CR126","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ebiom.2019.07.066","volume":"47","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, et al. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 2019;47:89\u201397.","journal-title":"EBioMedicine"},{"issue":"1","key":"704_CR127","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"704_CR128","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373\u20139.","journal-title":"Cancer Sci"},{"issue":"20","key":"704_CR129","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","volume":"15","author":"SM Ansell","year":"2009","unstructured":"Ansell SM, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15(20):6446\u201353.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"704_CR130","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399.","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00704-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00704-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T12:06:48Z","timestamp":1727611608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00704-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00704-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"10 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LSV is currently an employee and shareholder of Eli Lily and Company. LSV had advisory board relationships with Novartis, Boehringer Ingelheim, Helsinn, Kyowa Kirin, Regeneron, and Blueprint. She or her institution received research funding from Eli Lilly and Company, Soligenix, Helsinn, Eisai, Boehringer Ingelheim, Novartis, AbbVie, BMS, Celgene, Glenmark, Kyowa Kirin, Amgen, AnaptysBio, and Innate Pharma. LSV has been a speaker for Helsinn and Kyowa Kirin. These disclosures are not relevant to the current article. The rest of the authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Photo consent was obtained for all clinical photos included within this article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A.K., S.K., and L.H. drafted the manuscript. C.L.S., P.L.C., and L.S.V. provided important input. P.L.C. and L.S.V. supervised the process. All authors reviewed and edited the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}